UBS Maintains Buy Rating on MBX Biosciences with $60 Price Target
MBX Biosciences has surged over 230% in the past year as it advances a new GLP-1 treatment. UBS analyst Michael Yee maintains a buy rating and sets a $60 price target, implying nearly 50% upside from recent levels due to promising early trial data showing efficacy comparable or better than Eli Lilly's tirzepatide.
Topics: biotech GLP-1 drugs MBX Biosciences UBS analyst report